Influence of statistician involvement on reporting of randomized clinical trials in medical oncology

Anti-Cancer Drugs

Volumn 24, Issue 3, 2013, Pages 306-309

  Péron, Julien ^a,b   You, Benoit ^a   Gan, Hui K ^c,d   Maillet, Denis ^a   Chen, Eric X ^d   Pond, Gregory R ^e  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^c AUSTIN HOSPITAL   (Australia)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

methods; neoplasms; randomized controlled trials as topic; research designs; research standards; statistics as topic

Indexed keywords

ARTICLE; E-MAIL; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGY; PRIORITY JOURNAL; PUBLICATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS;

DATA COLLECTION; HUMANS; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH PERSONNEL;

EID: 84873412159     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835c3561     Document Type: Article

References (15)

1. Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: Review. BMJ 2009; 338:b1732
2. Lai R, Chu R, Fraumeni M, Thabane L. Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol 2006; 24:1136-1144
3. Rios LP, Odueyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. J Clin Endocrinol Metab 2008; 93:3810-3816
4. Toulmonde M, Bellera C, Mathoulin-Pelissier S, Debled M, Bui B, Italiano A. Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol 2011; 29:1204-1209
5. Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, et al. Quality of reporting of modern randomized controlled trials in medical oncology, a systematic review. J Natl Cancer Inst 2012; 104:982-989
6. Carroll KJ. Back to basics: Explaining sample size in outcome trials, are statisticians doing a thorough job? Pharm Stat 2009; 8:333-345
7. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288:358-362
8. Simon R. The role of statisticians in intervention trials. Stat Methods Med Res 1999; 8:281-286
9. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. 2010. Available at: Http://www.icmje.org/urm-full.pdf [Accessed 20 November 2012
10. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340:c869
11. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191-1194
12. You B, Gan H, Pond G, Chen XE. Consistency in the analysis and reporting of primary endpoints in oncology randomized controlled trials from registration to publication: A systematic review. J Clin Oncol 2012; 30: 210-216
13. Jaykaran Chavda N, Yadav P. Proper reporting of statistical parameters in clinical trials published in Indian medical journals. Is inclusion of statistician play any significant rolëJ Young Pharm 2011; 3:167-168
14. Wren JD, Grissom JE, Conway T. E-mail decay rates among corresponding authors in MEDLINE. EMBO Rep 2006; 7:122-127
15. Sheehan K. E-mail survey response rates: A review. J Comput Mediat Commun 2001; 6:Available at: Http://jcmc.indiana.edu/vol6/issue2/sheehan.html [Accessed 26 November 2012